



PRIOR AUTHORIZATION POLICY

- POLICY:** Vesicular Monoamine Transporter Type 2 Inhibitors – Tetrabenazine Prior Authorization Policy
- Xenazine® (tetrabenazine tablets – Lundbeck, generic)

REVIEW DATE: 04/10/2024

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Tetrabenazine, a vesicular monoamine transporter type 2 inhibitor, is indicated for the treatment of **chorea associated with Huntington's disease** in adults.¹

Clinical Efficacy

There are several published studies which have assessed the efficacy and safety of tetrabenazine for the treatment of other hyperkinetic movement disorders (e.g., tics in Tourette syndrome and tardive dyskinesia).²⁻⁴ While most of the data for treatment of Tourette syndrome indicate that antipsychotic medications, both typical and atypical, are most effective, other medications (including tetrabenazine) may be used first to avoid the potential side effects of dopamine blockade.⁵

Guidelines

The American Academy of Neurology (AAN) evidence-based guidelines on pharmacologic treatment of chorea in Huntington's disease (2012) state that if chorea in Huntington's disease requires treatment, clinicians should prescribe tetrabenazine, amantadine, or Rilutek® (riluzole tablets) [Level B].⁶

The AAN published an evidence-based guideline for the treatment of tardive syndromes (2013).⁷ The authors found that tetrabenazine possibly reduces tardive syndrome symptoms (based on two consistent Class III studies). Therefore, tetrabenazine may be considered in treating tardive syndromes (Level C).

The AAN published practice guideline recommendations for the treatment of tics in patients with Tourette syndrome and chronic tic disorders (2019).⁸ The guidelines state that the dopamine depleters, tetrabenazine, deutetrabenazine, and valbenazine, are lacking published, randomized, controlled trials in the treatment of tics but note that these drugs are increasingly used off-label. When appropriately dosed, these drugs are generally well-tolerated but may be associated with drowsiness, depression, and parkinsonism.

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of tetrabenazine. All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with tetrabenazine as well as the monitoring required for adverse events and long-term efficacy, approval requires tetrabenazine to be prescribed by or in consultation with a physician who specializes in the condition being treated.

• **Xenazine® (tetrabenazine tablets (Lundbeck, generic) is(are) covered as medically necessary when the following criteria is(are) met for FDA-approved indication(s) or other uses with supportive evidence (if applicable):**

FDA-Approved Indication

- 1. Chorea Associated with Huntington's Disease.** Approve for 1 year if the patient meets ALL of the following (A, B, and C):
 - A) Patient is \geq 18 years of age; AND
 - B) Diagnosis of Huntington's disease is confirmed by genetic testing (for example, an expanded HTT CAG repeat sequence of at least 36); AND
 - C) The medication is prescribed by or in consultation with a neurologist.

Other Uses with Supportive Evidence

- 2. Hyperkinetic Dystonia.** Approve for 1 year if the patient meets BOTH of the following (A and B):
 - A) Patient is \geq 18 years of age; AND
 - B) The medication is prescribed by or in consultation with a neurologist.
- 3. Tardive Dyskinesia.** Approve for 1 year if the patient meets BOTH of the following (A and B):
 - A) Patient is \geq 18 years of age; AND
 - B) The medication is prescribed by or in consultation with a neurologist or psychiatrist.

- 4. Tourette Syndrome and Related Tic Disorders.** Approve for 1 year if the patient meets BOTH of the following (A and B):
- A) Patient is \geq 18 years of age; AND
 - B) The medication is prescribed by or in consultation with a neurologist.

CONDITIONS NOT COVERED

Xenazine® (tetrabenazine tablets (Lundbeck, generic) is(are) considered experimental, investigational or unproven for ANY other use(s)

REFERENCES

1. Xenazine® tablets [prescribing information]. Deerfield, IL: Lundbeck; November 2019.
2. Merative Micromedex®. Merative US. Available at: <https://www.micromedexsolutions.com/>. Accessed on April 3, 2024. Search terms: tetrabenazine.
3. Chen JJ, Ondo WG, Dashtipour K, et al. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. *Clin Ther.* 2012;34(7):1487-504.
4. Guay DR. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. *Am J Geriatr Pharmacother.* 2010;8(4):331-373.
5. Quezada J, Coffman KA. Current Approaches and New Developments in the Pharmacological Management of Tourette Syndrome. *CNS Drugs.* 2018; 32(1):33-45.
6. Armstrong MJ, Miyasaki JM. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. *Neurology.* 2012;79:597-603.
7. Bhidayasiri R, Fahn S, Weiner WJ, et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology.* 2013;81(5):463-469.
8. Pringsheim T, Okun MS, Müller-Vahl K, et al. Practice guideline recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. *Neurology.* 2019;92:896-906.

HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes.	06/07/2023
Annual Revision	No criteria changes.	04/10/2024

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2024 The Cigna Group.